An observational study in Liver Cirrhosis, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University Health Network, Toronto · Observational
This is a prospective, pre-post implementation study designed to evaluate how artificial intelligence-based selection committee (AI-SC) recommendations affect decision-making when integrated into routine clinical workflows. The study will focus on individual liver transplant candidacy decisions as the primary unit of analysis. Researchers will observe and analyze these decisions during weekly University Health Network (UHN) Liver Transplant Selection Committee meetings over an approximate 12-month period. The goal is to determine if the deployment of AI-SC recommendations changes, optimizes, or influences the committee's final transplant candidacy determinations compared to baseline practices.
The study will be conducted over an approximate 12-month period during regular weekly UHN Liver Transplant Selection Committee meetings. The primary unit of analysis is the individual liver transplant candidacy decision. The AI-SC output is then presented as an advisory decision-support summary. The committee may maintain or modify its decision and/or rationale. The final decision remains the decision of the human committee.
The study utilizes a pre-post implementation design:
Objectives and Evaluated Metrics The primary objective is to evaluate the direct effect of AI-SC recommendations on committee decision-making when deployed prospectively.
To comprehensively assess this impact, the secondary objectives will systematically measure:
Eligibility Criteria:
Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No
Inclusion Criteria:
Exclusion Criteria:
1,298 studies on the registry are indexed under Liver Cirrhosis; 338 are open to participants now.
This study's planned enrollment of 200 is above the median of 171 across 526 observational studies indexed under Liver Cirrhosis.
Browse Liver Cirrhosis studies →University Health Network, Toronto is the lead sponsor of 1,438 studies on the registry; 297 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with liver cirrhosis assessed for liver transplantation at UHN who may be presented at the weekly UHN Liver Transplant Selection Committee meeting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Refusal to participate will not affect transplant assessment, committee review, clinical management, waitlist eligibility, or access to future care.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The AI-SC is an investigational clinical decision-support tool designed to provide a structured advisory recommendation for liver transplant candidacy discussions. It consists of six specialty-specific LLM-based agents representing hepatology, transplant surgery, cardiology, anesthesiology, psychiatry, and social work. The system uses a retrieval-augmented generation framework that references a locked knowledge base of institutional transplant criteria and relevant clinical guidelines.
Frequency of modification of transplant committee decisions after presentation of the AI-SC recommendation, measured as the proportion of cases in which the final post-AI decision differs from the recorded initial pre-AI decision
Time frame: During weekly UHN Liver Transplant Selection Committee meetings for approximately 12 months.
Plan to share: No — Participant privacy and confidentiality.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
Of 231 non-industry observational studies under Liver Cirrhosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 12 months is below that.
Counting every sponsor, half of 247 studies reached it within 47 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →